

Giuseppe Lo Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8724269/publications.pdf>

Version: 2024-02-01

106
papers

2,444
citations

186265

28
h-index

233421

45
g-index

107
all docs

107
docs citations

107
times ranked

4516
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315
2	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	4.5	151
3	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	7.7	124
4	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. <i>Tumor Biology</i> , 2014, 35, 6195-6206.	1.8	91
5	Italian Nivolumab Expanded Access Program in Nonsquamous Nonâ€“Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77
6	Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 48.	8.6	72
7	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 2166-2173.	7.0	67
8	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. <i>Oncologist</i> , 2020, 25, 94-98.	3.7	58
9	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	3.7	57
10	Cognitive impairment and chemotherapy: a brief overview. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 7-14.	4.4	55
11	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	1.3	54
12	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 72-78.	2.0	54
13	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016, 37, 7047-7057.	1.8	46
14	Pozotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. <i>European Journal of Cancer</i> , 2021, 149, 235-248.	2.8	46
15	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 38-42.	2.0	44
16	Circulating tumor cells in high-risk nonmetastatic colorectal cancer. <i>Tumor Biology</i> , 2013, 34, 2507-2509.	1.8	40
17	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. <i>Frontiers in Oncology</i> , 2018, 8, 650.	2.8	40
18	Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. <i>Journal of Cancer</i> , 2014, 5, 301-310.	2.5	39

#	ARTICLE	IF	CITATIONS
19	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	3.7	39
20	Cysts of the canal of Nuck: ultrasound and magnetic resonance imaging findings. <i>Journal of Ultrasound</i> , 2009, 12, 125-127.	1.3	36
21	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 167-176.	4.4	35
22	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	4.0	35
23	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	3.7	35
24	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 $\geq 50\%$ advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	4.5	35
25	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	1.4	35
26	Concomitant <i>EML4-ALK</i> rearrangement and <i>EGFR</i> mutation in non-small cell lung cancer patients: a literature review of 100 cases. <i>Oncotarget</i> , 2017, 8, 59889-59900.	1.8	33
27	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score $\geq 50\%$ treated with front-line pembrolizumab. <i>Acta Oncologica</i> , 2020, 59, 1058-1063.	1.8	31
28	Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1411-1416.	2.5	30
29	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. <i>Translational Lung Cancer Research</i> , 2016, 5, 563-578.	2.8	30
30	Breast cancer metastatic to the pituitary gland: a case report. <i>World Journal of Surgical Oncology</i> , 2012, 10, 137.	1.9	29
31	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , 2018, 115, 135-142.	2.0	27
32	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	3.0	25
33	Fertility drugs, reproductive strategies and ovarian cancer risk. <i>Journal of Ovarian Research</i> , 2014, 7, 51.	3.0	23
34	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	2.0	23
35	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 183-188.	3.2	20
36	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 41.	4.0	20

#	ARTICLE	IF	CITATIONS
37	Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas. <i>Current Cancer Drug Targets</i> , 2012, 12, 1016-1031.	1.6	19
38	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	3.1	18
39	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. <i>Tumori</i> , 2018, 104, 88-95.	1.1	17
40	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	2.0	17
41	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021, 22, 161-169.	2.6	17
42	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016, 37, 12991-13003.	1.8	16
43	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987772.	3.2	16
44	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	3.6	15
45	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e180-e192.	2.6	15
46	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016, 7, 44841-44847.	1.8	15
47	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 435.	3.7	14
48	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13
49	Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 457.	2.0	12
50	Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. <i>Tumori</i> , 2017, 103, 325-337.	1.1	12
51	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
52	Breast cancer risk after exposure to fertility drugs. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 149-157.	2.4	11
53	Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). <i>Cancer Management and Research</i> , 2013, 5, 377.	1.9	10
54	Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. <i>Tumor Biology</i> , 2014, 35, 8415-8424.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 52.	0.8	10
56	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. <i>Cancers</i> , 2021, 13, 1300.	3.7	10
57	Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	10
58	Emerging Role of Cetuximab in the Treatment of Colorectal Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2012, 7, 233-247.	1.6	9
59	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. <i>Molecular Therapy</i> , 2021, 29, 2963-2978.	8.2	9
60	Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. <i>Translational Lung Cancer Research</i> , 2016, 5, 110-4.	2.8	9
61	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. <i>Tumori</i> , 2016, 102, 18-30.	1.1	8
62	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	2.8	8
63	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. <i>Current Drug Targets</i> , 2017, 18, 341-362.	2.1	8
64	Subcutaneous metastases from colon cancer: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 212.	0.8	7
65	Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet. <i>Tumori</i> , 2016, 102, 223-225.	1.1	7
66	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019, 15, 2743-2757.	2.4	7
67	Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. <i>Tumori</i> , 2019, 105, NP57-NP62.	1.1	7
68	A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 161.	0.8	6
69	Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. <i>Tumori</i> , 2016, 102, 337-351.	1.1	6
70	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018, 40, 101042831881504.	1.8	6
71	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2019, 20, e652-e660.	2.6	6
72	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-“Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020, 21, e337-e348.	2.6	6

#	ARTICLE	IF	CITATIONS
73	Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
74	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017, 13, 1677-1683.	2.4	5
75	FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods. <i>Tumori</i> , 2017, 103, 360-366.	1.1	5
76	ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?. <i>Thrombosis Research</i> , 2020, 194, 176-177.	1.7	5
77	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103299.	4.4	5
78	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016, 9, 432-439.	0.7	4
79	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 969-976.	2.4	4
80	Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9106-9106.	1.6	4
81	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1940-1951.	2.8	4
82	Clinical use of fertility agents and risk of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 130-137.	2.0	3
83	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 353-361.	2.4	3
84	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , 2019, 15, 3015-3024.	2.4	3
85	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 35-35.	1.8	3
86	Recurrent thrombosis followed by Lazarus response in <i>ROS1</i> rearranged NSCLC treated with crizotinib: a case report. <i>Tumori</i> , 2020, 106, NP41-NP45.	1.1	3
87	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. <i>Future Oncology</i> , 2022, 18, 2593-2604.	2.4	3
88	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020, 5, e000748.	4.5	2
89	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	2.8	2
90	Is CEA Better than CYFRA 21-1 in the Monitoring of Squamous Cell Lung Cancer Progression?. <i>Medical Principles and Practice</i> , 2011, 20, 200-200.	2.4	1

#	ARTICLE	IF	CITATIONS
91	Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan. <i>Annals of Oncology</i> , 2016, 27, vi509.	1.2	1
92	Complete response to avelumab in Merkel Cell Carcinoma, and potential correlation with toxicity: a case report. <i>Annals of Oncology</i> , 2016, 27, iv119.	1.2	1
93	Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. <i>Thoracic Cancer</i> , 2020, 11, 1661-1669.	1.9	1
94	Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100).. <i>Journal of Clinical Oncology</i> , 2014, 32, e12005-e12005.	1.6	1
95	G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)?. <i>Journal of Clinical Oncology</i> , 2014, 32, e20672-e20672.	1.6	1
96	The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014, 32, e12000-e12000.	1.6	1
97	Is hyperprogressive disease a specific phenomenon of immunotherapy?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.8	1
98	Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: the MetNET-2 trial. <i>Annals of Oncology</i> , 2016, 27, iv25.	1.2	0
99	Impact of Hyponatremia in a Tertiary Cancer Center: a one-year-Survey at National Cancer Institute of Milan. <i>Annals of Oncology</i> , 2016, 27, iv112.	1.2	0
100	Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging. <i>Annals of Oncology</i> , 2016, 27, iv13.	1.2	0
101	Safety of lanreotide 120 mg ATG in combination with metformin in patients with advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: The MetNET-2 trial. <i>Annals of Oncology</i> , 2016, 27, vi148.	1.2	0
102	209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, S147.	1.1	0
103	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. <i>ESMO Open</i> , 2021, 6, 100034.	4.5	0
104	“Long extended” temozolomide in a selected population with not radically resected high-grade gliomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12510-e12510.	1.6	0
105	Facing the First-line in Metastatic Non-small-cell Lung Cancer “ Immunotherapy and Chemotherapy. <i>European Oncology and Haematology</i> , 2020, 16, 39.	0.0	0
106	mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1940-1951.	2.8	0